CD19 and diffuse large B-cell lymphoma: Two CAR-T cell therapies targeting CD19 in pediatric B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) were approved in the United States in 2017, and the European Union in 2018.